2 búsqueda de la palabra clave 'treatment outcome'

Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia / Andrés Felipe Valencia Quintero ; Natalia Andrea Rojas Henao ; Enyd Estefanía Rave Builes ; Nieto López, Emmanuel Salvador  

Público ISBD Título : Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia Tipo de documento : documento electrónico Autores : Andrés Felipe Valencia Quintero, Autor ; Natalia Andrea Rojas Henao, Autor ; Enyd Estefanía Rave Builes, Autor ; Nieto López, Emmanuel Salvador, Autor Fecha de publicación : 2025 Títulos uniformes : Hospital Practice Idioma : Inglés (eng) Palabras clave : Porphyria  hematin  heme arginate  treatment outcome  Drug effects Resumen : Background: Porphyria is an orphan disease classified as a genetic disorder caused by a partial or high-grade deficiency of enzymes involved in the synthesis of heme, an essential component of hemoglobin.This deficiency results in the accumulation of porphyrins (ALAS1 and PBG), intermediates in the hememetabolic pathway. This accumulation triggers porphyria attacks. In Colombia the Heme Arginate andHuman Hematin are the therapeutics alternatives for the management of porphyria AttacksObjective: To evaluate the comparative effectiveness of heme arginate versus human hemin fortreating porphyria attacks in hospitalized patients across three institutions in Medellin, Colombia.Methods: An observational and analytical study was conducted to compare the outcomes of treatmentwith human hematin versus heme arginate in clinical episodes of patients diagnosed with porphyriabetween 2015–2021.Results: In episodes treated with heme arginate (ArgH), 75% achieved pain control or reduction, 41.6%showed a reduction in opioid dosage, and 88.8% achieved resolution of the Porphyria attack. Forepisodes treated with human hematin (HH), 85.3% achieved pain control or reduction, 53.6% showeda reduction in opioid dosage, and 90.2% achieved resolution of the attack. When evaluating theeffectiveness of both treatments, no statistically significant differences were observed across thethree predefined effectiveness outcomes of the study.Conclusions: This study provides a comparative evaluation of heme arginate (ArgH) and humanhematin (HH) in the management of Porphyria attacks, demonstrating that both treatments are similarlyeffective in achieving pain control, reducing opioid use, and resolving clinical attacks. Mención de responsabilidad : Natalia A Rojas Henao, Andres Felipe Valencia, Emmanuel Salvador Nieto López DOI (Digital Object Identifier) : 10.1080/21548331.2025.2520743 Derechos de uso : CC BY-NC-ND En línea : https://www.tandfonline.com/doi/full/10.1080/21548331.2025.2520743#abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia [documento electrónico] / Andrés Felipe Valencia Quintero, Autor ; Natalia Andrea Rojas Henao, Autor ; Enyd Estefanía Rave Builes, Autor ; Nieto López, Emmanuel Salvador, Autor . - 2025. Obra : Hospital Practice Idioma : Inglés (eng) Palabras clave : Porphyria  hematin  heme arginate  treatment outcome  Drug effects Resumen : Background: Porphyria is an orphan disease classified as a genetic disorder caused by a partial or high-grade deficiency of enzymes involved in the synthesis of heme, an essential component of hemoglobin.This deficiency results in the accumulation of porphyrins (ALAS1 and PBG), intermediates in the hememetabolic pathway. This accumulation triggers porphyria attacks. In Colombia the Heme Arginate andHuman Hematin are the therapeutics alternatives for the management of porphyria AttacksObjective: To evaluate the comparative effectiveness of heme arginate versus human hemin fortreating porphyria attacks in hospitalized patients across three institutions in Medellin, Colombia.Methods: An observational and analytical study was conducted to compare the outcomes of treatmentwith human hematin versus heme arginate in clinical episodes of patients diagnosed with porphyriabetween 2015–2021.Results: In episodes treated with heme arginate (ArgH), 75% achieved pain control or reduction, 41.6%showed a reduction in opioid dosage, and 88.8% achieved resolution of the Porphyria attack. Forepisodes treated with human hematin (HH), 85.3% achieved pain control or reduction, 53.6% showeda reduction in opioid dosage, and 90.2% achieved resolution of the attack. When evaluating theeffectiveness of both treatments, no statistically significant differences were observed across thethree predefined effectiveness outcomes of the study.Conclusions: This study provides a comparative evaluation of heme arginate (ArgH) and humanhematin (HH) in the management of Porphyria attacks, demonstrating that both treatments are similarlyeffective in achieving pain control, reducing opioid use, and resolving clinical attacks. Mención de responsabilidad : Natalia A Rojas Henao, Andres Felipe Valencia, Emmanuel Salvador Nieto López DOI (Digital Object Identifier) : 10.1080/21548331.2025.2520743 Derechos de uso : CC BY-NC-ND En línea : https://www.tandfonline.com/doi/full/10.1080/21548331.2025.2520743#abstract Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD002385	AC-2025-068	Archivo digital	Producción Científica	Artículos científicos	Disponible

Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents / Juan Ignacio Marín Zuluaga ; Óscar Mauricio Santos Sánchez    

Público ISBD Título : Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents Otros títulos : Experiencia colombiana en el tratamiento de la hepatitis C con agentes antivirales de acción directa Tipo de documento : documento electrónico Autores : Juan Ignacio Marín Zuluaga, ; Óscar Mauricio Santos Sánchez, Fecha de publicación : 2019 Títulos uniformes : Medicina (Buenos Aires) Idioma : Inglés (eng) Palabras clave : Antiviral agents  drug therapy  hepatitis C  chronic hepatitis  liver transplantation  treatment outcome Resumen : There are few published real-world studies on hepatitis C in Latin America. This paper describes a cohort of Colombian subjects treated with direct-acting antiviral agents. A total of 195 patients from 5 hepatology centers in 4 Colombian cities were retrospectively studied. For each patient, serum biomarkers were obtained, and Child-Pugh, MELD, cirrhosis and fibrosis stage were calculated. Additionally, viral load was quantified at initiation, end of treatment and at 12 weeks of completion. Adverse effects were recorded. Patients with liver transplant were compared with non-transplanted patients in terms of serum biomarkers. The patients had received 9 different regimes. The most prevalent viral genotype was 1b (81.5%). Overall, 186 patients (95.4%) attained sustained virologic response. When comparing transplanted vs. non-transplanted patients, those in the non-transplanted group were more likely to have cirrhosis (52.6% vs. 12.5%, p = 0.0004). Pre-treatment viral load was higher in the transplant group (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p Mención de responsabilidad : Adriana Varón, Luisa Santos, Mónica Tapias, Clara Cáez, Juan Ignacio Marín, Oscar Santos, Martín Garzón, Oscar Beltrán, Andrés Gómez-Aldana, Ismael J Yepes, Martín Rondón, Diego Rosselli Referencia : Medicina (B Aires). 2019;79(1):29-36 PMID : 30694186 Derechos de uso : CC BY-NC En línea : http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-768020190001000 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents = Experiencia colombiana en el tratamiento de la hepatitis C con agentes antivirales de acción directa [documento electrónico] / Juan Ignacio Marín Zuluaga, ; Óscar Mauricio Santos Sánchez,  . - 2019. Obra : Medicina (Buenos Aires) Idioma : Inglés (eng) Palabras clave : Antiviral agents  drug therapy  hepatitis C  chronic hepatitis  liver transplantation  treatment outcome Resumen : There are few published real-world studies on hepatitis C in Latin America. This paper describes a cohort of Colombian subjects treated with direct-acting antiviral agents. A total of 195 patients from 5 hepatology centers in 4 Colombian cities were retrospectively studied. For each patient, serum biomarkers were obtained, and Child-Pugh, MELD, cirrhosis and fibrosis stage were calculated. Additionally, viral load was quantified at initiation, end of treatment and at 12 weeks of completion. Adverse effects were recorded. Patients with liver transplant were compared with non-transplanted patients in terms of serum biomarkers. The patients had received 9 different regimes. The most prevalent viral genotype was 1b (81.5%). Overall, 186 patients (95.4%) attained sustained virologic response. When comparing transplanted vs. non-transplanted patients, those in the non-transplanted group were more likely to have cirrhosis (52.6% vs. 12.5%, p = 0.0004). Pre-treatment viral load was higher in the transplant group (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p Mención de responsabilidad : Adriana Varón, Luisa Santos, Mónica Tapias, Clara Cáez, Juan Ignacio Marín, Oscar Santos, Martín Garzón, Oscar Beltrán, Andrés Gómez-Aldana, Ismael J Yepes, Martín Rondón, Diego Rosselli Referencia : Medicina (B Aires). 2019;79(1):29-36 PMID : 30694186 Derechos de uso : CC BY-NC En línea : http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-768020190001000 [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001243	AC-2019-032	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2019-032.pdf Adobe Acrobat PDF